Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic …
VHJ van der Velden, JG te Marvelde… - Blood, The Journal …, 2001 - ashpublications.org
Antibody-targeted chemotherapy is a promising therapy in patients with acute myeloid
leukemia (AML). In a phase II study of Mylotarg (CMA-676, gemtuzumab ozogamicin), which …
leukemia (AML). In a phase II study of Mylotarg (CMA-676, gemtuzumab ozogamicin), which …
Pharmacokinetics of gemtuzumab ozogamicin, an antibody‐targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse
JA Dowell, J Korth‐Bradley, H Liu… - The Journal of …, 2001 - Wiley Online Library
The purpose of this study was to characterize the pharmacokinetics of gemtuzumab
ozogamicin (Mylotarg™; Wyeth‐Ayerst Laboratories, St. Davids, PA) in patients with acute …
ozogamicin (Mylotarg™; Wyeth‐Ayerst Laboratories, St. Davids, PA) in patients with acute …
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia
PF Bross, J Beitz, G Chen, XH Chen, E Duffy… - Clinical cancer …, 2001 - AACR
Abstract Purpose: Gemtuzumab ozogamicin (Mylotarg; Wyeth Laboratories, Philadelphia,
PA) consists of a semisynthetic derivative of calicheamicin, a cytotoxic antibiotic linked to a …
PA) consists of a semisynthetic derivative of calicheamicin, a cytotoxic antibiotic linked to a …
Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody− calicheamicin conjugate for treatment of acute myeloid leukemia
PR Hamann, LM Hinman, I Hollander… - Bioconjugate …, 2002 - ACS Publications
CD33 is expressed by acute myeloid leukemia (AML) cells in> 80% of patients but not by
normal hematopoietic stem cells, suggesting that elimination of CD33+ cells may be …
normal hematopoietic stem cells, suggesting that elimination of CD33+ cells may be …
Mylotarg: antibody-targeted chemotherapy comes of age
EL Sievers, M Linenberger - Current opinion in oncology, 2001 - journals.lww.com
Abstract Mylotarg (gemtuzumab ozogamicin, CMA-676; Wyeth-Ayerst Laboratories,
Philadelphia, PA) recently was approved by the US Food and Drug Administration for the …
Philadelphia, PA) recently was approved by the US Food and Drug Administration for the …
High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg®) treatment in acute myeloid leukemia patients
VHJ van der Velden, N Boeckx, I Jedema… - Leukemia, 2004 - nature.com
Gemtuzumab ozogamicin (Mylotarg®) induces remission in approximately 30% of relapsed
AML patients. We previously demonstrated that gemtuzumab infusion results in near …
AML patients. We previously demonstrated that gemtuzumab infusion results in near …
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial
AK Burnett, RK Hills, D Milligan, L Kjeldsen… - Journal of clinical …, 2011 - ascopubs.org
Purpose Antibody-directed chemotherapy for acute myeloid leukemia (AML) may permit
more treatment to be administered without escalating toxicity. Gemtuzumab ozogamicin …
more treatment to be administered without escalating toxicity. Gemtuzumab ozogamicin …
Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies
JF DiJoseph, DC Armellino, ER Boghaert, K Khandke… - Blood, 2004 - ashpublications.org
Antibody-targeted chemotherapy with gemtuzumab ozogamicin (CMA-676, a CD33-targeted
immunoconjugate of N-acetyl-γ-calicheamicin dimethyl hydrazide [CalichDMH], a potent …
immunoconjugate of N-acetyl-γ-calicheamicin dimethyl hydrazide [CalichDMH], a potent …
Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia
S Lapusan, MB Vidriales, X Thomas, S De Botton… - Investigational new …, 2012 - Springer
The efficacy of anti-CD33 immunoconjugates had been previously demonstrated for
gemtuzumab-ozogamicin. AVE9633 is an anti-CD33-maytansine conjugate created by …
gemtuzumab-ozogamicin. AVE9633 is an anti-CD33-maytansine conjugate created by …
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
EL Sievers, RA Larson, EA Stadtmauer… - Journal of Clinical …, 2001 - ascopubs.org
PURPOSE: Three open-label, multicenter trials were conducted to evaluate the efficacy and
safety of single-agent Mylotarg (gemtuzumab ozogamicin; CMA-676; Wyeth Laboratories …
safety of single-agent Mylotarg (gemtuzumab ozogamicin; CMA-676; Wyeth Laboratories …